Half-Priced Humalog Highlights Uncertainties Of Insulin Transition

Eli Lilly is halving the list price on two more of its insulin products for consumers who either are uninsured or choose to buy the products without insurance, the company announced Tuesday (Jan. 14). Some sources say Lilly’s tactic could forestall Humalog biosimilars once insulin is transitioned from a drug to a biologic in March, but others say the authorized generics will not affect biosimilar competition. Lilly is creating authorized generics of the products to avoid paying rebates on them...